For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Tirzepatide
Illustration for Tirzepatide

THE PEPSRADAR ENCYCLOPEDIA

Tirzepatide

Incretin-related glucose and appetite regulation

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Tirzepatide · KEY FACTS

Content updated · how dates work

Saved peptides

Half-life source: FDA label (MOUNJARO) on DailyMed ↗

Compare: Semaglutide vs Tirzepatide · Tirzepatide vs Retatrutide

What is Tirzepatide?

Tirzepatide is a dual-incretin medicine with distinct product and indication contexts. Its clinical-trial material is not interchangeable with a research-use vial.

Video overview · 3:05

Tirzepatide: What the Trials Actually Show (Mounjaro and Zepbound Explained)

How it acts on two gut-hormone targets, what the SURMOUNT and SURPASS trials found (including a head-to-head trial against semaglutide), the side effects and label warnings, the outcome trials still under way, and its FDA approvals.

Narrated with an AI voice from this profile's sources; education only, no dosing.

Read the transcript

Tirzepatide is a prescription medicine, sold as Mounjaro for type 2 diabetes and as Zepbound for weight management and sleep apnea. It acts on two gut hormone targets at once, and it has been tested in large trials with thousands of people. Here is what those trials actually show.

Tirzepatide is a single molecule that switches on receptors for two gut hormones, GIP and GLP-1. GLP-1 helps regulate appetite, and animal studies suggest GIP adds to that effect. People eat fewer calories, the body releases more insulin when blood sugar is high, and the stomach empties more slowly. How much the GIP part adds in people is less clear.

In SURMOUNT-1, about twenty-five hundred adults with obesity but no diabetes lost about fifteen to twenty-one percent of their weight on average over seventy-two weeks, versus about three percent on placebo. In SURMOUNT-5, a head-to-head trial, people lost about twenty percent on tirzepatide and fourteen percent on semaglutide. In sleep apnea, breathing interruptions fell by about twenty-five to twenty-nine an hour, versus about five on placebo.

The most common side effects are digestive: nausea, diarrhea, vomiting and constipation, mostly mild to moderate. The label also warns about pancreatitis, gallbladder disease, and kidney injury from dehydration. And it carries a boxed warning: tirzepatide caused thyroid tumors in rats, and whether it does in humans is unknown.

Long-term outcomes are the big open question. A trial of more than fifteen thousand adults with obesity is testing whether tirzepatide lowers deaths, heart attacks, strokes and heart failure events, with results expected in 2027. Another is testing it in teenagers with obesity.

Tirzepatide is FDA approved. Mounjaro was approved in 2022 for type 2 diabetes, after the SURPASS trials, and in 2026 also to lower the risk of heart attack, stroke and heart-related death in high-risk adults with diabetes. Zepbound is approved for weight management and for sleep apnea with obesity. Compounded copies are not FDA approved, and the FDA has warned sellers of so-called research versions.

Is Zepbound the same drug as Mounjaro? Yes, both are tirzepatide, approved for different uses. Does the weight stay off after stopping? In SURMOUNT-4, people switched to placebo regained much of what they had lost. And is compounded or research tirzepatide the approved drug? No. The FDA does not review compounded drugs before sale, and research vials have none of the manufacturing oversight.

The bottom line: tirzepatide is an approved medicine with large effects on weight and blood sugar, common digestive side effects, and outcome trials still under way. For every study and source, see the tirzepatide profile on PepsRadar dot com.

Biological role or research focus

Incretin-related glucose and appetite regulation.

Mounjaro, Zepbound, compounded preparations, and research products have distinct identities.

Role reference: MedlinePlus: Tirzepatide injection ↗

Names you may encounter

Mounjaro · Zepbound

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
GIP / GLP-1 receptor agonist
Main research area
Diabetes, weight, and related indications
Evidence featured
Human randomized trial
Source check
October 4, 2026

Source: MedlinePlus: Tirzepatide injection ↗

Quick answers

Is Tirzepatide FDA approved?
Yes. Mounjaro (NDA 215866, approved May 2022) for type 2 diabetes in adults, extended to children 10 and older in December 2025, and in August 2026 to lower the risk of heart attack, stroke and heart-related death in high-risk adults with type 2 diabetes. Source ↗
Is Tirzepatide safe?
Tirzepatide is a GIP/GLP-1 drug for weight and diabetes; stomach side effects are common, and the label warns of thyroid C-cell tumors in rats, pancreatitis, gallbladder disease and kidney injury. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Tirzepatide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
Has the FDA taken action over Tirzepatide?
Yes. Our records list 4 FDA actions naming it, most recently on November 9, 2026: FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

4 Human research
StudyTypePopulation / model
SURMOUNT-1 (2022)Human randomized trial2,539 adults with obesity, or overweight and a weight-related complication, without diabetes.
T-REx: resistance exercise during tirzepatide treatment (2026)Human randomized trial120 adults with overweight or obesity, all treated with tirzepatide, at the University of Western Australia.
SURPASS-2 direct comparison in type 2 diabetes (2021)Human randomized trial1,879 patients with type 2 diabetes; mean baseline HbA1c 8.28%.
SURMOUNT-4 · continuation versus withdrawal (2024)Human randomized withdrawal trial670 adults with overweight or obesity without diabetes who completed a 36-week open-label lead-in; 783 initially enrolled.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2022

SURMOUNT-1

Tirzepatide Once Weekly for the Treatment of Obesity.

Population / model
2,539 adults with obesity, or overweight and a weight-related complication, without diabetes.
Study design
Seventy-two-week blinded placebo-controlled study with gradual escalation.
Main finding
Mean weight reductions were 15.0%, 19.5%, and 20.9% across active groups versus 3.1% with placebo. Gastrointestinal effects were common.
Limits & context
This trial cannot be compared directly with STEP 1 as if participants were randomized between the two drugs. Outcomes depend on population, duration, regimen, and handling of discontinuation.

Source: Tirzepatide Once Weekly for the Treatment of Obesity. ↗

Human randomized trial · 2026

T-REx: resistance exercise during tirzepatide treatment

Does supervised strength training reduce the lean mass and strength lost while losing weight on tirzepatide?

Population / model
120 adults with overweight or obesity, all treated with tirzepatide, at the University of Western Australia.
Study design
Two-arm randomized trial: tirzepatide alone (usual activities) versus tirzepatide plus supervised resistance exercise three times a week, for 40 weeks. Primary outcomes: change in total fat mass and total lean soft tissue mass.
Main finding
Weight loss was similar (-22.6 kg alone, -22.3 kg with exercise), as was fat loss (-17.2 vs -18.0 kg). Lean soft tissue loss was smaller with exercise (-3.6 vs -4.7 kg). Strength fell on tirzepatide alone (bench press -4.1 kg, lat pulldown -4.4 kg, knee extension -4.4 kg) but rose with exercise (+4.7, +8.6 and +5.9 kg). Exercise sessions had 91% adherence, and most participants tolerated the full dose increase.
How to read it
Strength training did not change how much weight people lost, but it reduced lean mass loss and turned a measured loss of strength into a gain.
Limits & context
A 40-week trial in 120 people; it cannot show effects on falls, fractures or long-term function, and participants were not blinded to exercise. Several authors report speaker fees or advisory roles with Eli Lilly. Results apply to the approved drug used under medical supervision.

Source: T-REx · Nature Medicine · 2026 ↗

Human randomized trial · 2021

SURPASS-2 direct comparison in type 2 diabetes

How did the studied tirzepatide regimens compare with semaglutide in this diabetes trial?

Population / model
1,879 patients with type 2 diabetes; mean baseline HbA1c 8.28%.
Study design
Open-label randomized phase 3 trial lasting 40 weeks. Three tirzepatide groups were compared with semaglutide at its diabetes dose.
Main finding
Mean HbA1c fell by 2.01–2.30 percentage points in the tirzepatide groups and 1.86 with semaglutide. Weight reductions were greater with tirzepatide; between-group differences ranged from 1.9 to 5.5 kg. Gastrointestinal adverse effects were common.
How to read it
This is a direct comparison, but only for its actual regimens, population, and outcomes. HbA1c percentage points and percentage weight change are different measures.
Limits & context
Open-label design; the semaglutide comparator was its diabetes dose, not the higher weight-management dose. It is not a universal ranking across all products or doses. Funded by Eli Lilly.

Source: Frias et al. · NEJM · SURPASS-2 · 2021 ↗

Human randomized withdrawal trial · 2024

SURMOUNT-4 · continuation versus withdrawal

Was initial weight reduction maintained after switching to placebo?

Population / model
670 adults with overweight or obesity without diabetes who completed a 36-week open-label lead-in; 783 initially enrolled.
Study design
Randomized double-blind comparison of continued tirzepatide with placebo for another 52 weeks, alongside diet and activity.
Main finding
After a mean 20.9% reduction during lead-in, weight changed by −5.5% with continued treatment versus +14.0% with placebo from week 36 to week 88. At least 80% of the lead-in loss was maintained by 89.5% versus 16.6%.
How to read it
The randomized-period change and the total change from enrollment use different baselines. They should not be conflated.
Limits & context
Only lead-in completers were randomized. Gastrointestinal events were more common with continued treatment. This does not determine an individual stopping plan or prove that every patient will regain the same amount.

Source: Aronne et al. · JAMA · SURMOUNT-4 · 2024 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

79 registered studies name Tirzepatide as an intervention among the 100 most recently updated of 320 search results; 52 are recruiting or under way, 17 have not started recruiting yet and 10 completed. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584 · Eli Lilly and Company
Active, not recruitingPhase 42022-08-01794
A Study to Evaluate ALN-2232 in Participants With Obesity
NCT07463846 · Alnylam Pharmaceuticals
RecruitingPhase 1 / Phase 22026-03-02156
Breath Acetone During Tirzepatide Treatment and Resistance Training in Adults With Obesity
NCT07931235 · Technical University of Munich
Not yet recruiting2026-10-22150
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512 · Eli Lilly and Company
Active, not recruitingPhase 32022-10-1115374
Molecular and Microbiome Changes During Tirzepatide Treatment and Resistance Training in Obesity
NCT07931196 · Technical University of Munich
Not yet recruiting2026-10-22150
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
NCT07734792 · yifang zhu
RecruitingPhase 2 / Phase 32026-09-26726
GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial
NCT06162715 · Vanderbilt University Medical Center
Active, not recruitingPhase 2 / Phase 32024-10-3030
Functional, Cognitive, and Behavioral Correlates of Resistance Training During Tirzepatide-Induced Weight Loss
NCT07929571 · Technical University of Munich
Not yet recruiting2026-10-22150

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 79 listed studies.

Search additional PubMed records ↗

Risks & interactions

Tirzepatide is a GIP/GLP-1 drug for weight and diabetes; stomach side effects are common, and the label warns of thyroid C-cell tumors in rats, pancreatitis, gallbladder disease and kidney injury.

FDA boxed warning

Caused thyroid C-cell tumors in rats; it is unknown whether it does in humans. Do not use with a personal or family history of medullary thyroid carcinoma or with MEN 2.

Human safety data: FDA label

Safety is established by FDA labeling and large trials. This entry summarizes the Zepbound label; the diabetes brand Mounjaro has its own label. Whether the rat thyroid tumors matter for humans is unknown.

Take extra care with: Blood thinners or bleeding problemsDiabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeedingKidney problems

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Known serious allergy to tirzepatide or any ingredient
  • Severe gastroparesis (very slow stomach emptying): not recommended
  • Pregnancy: may cause fetal harm, and the label says to stop when pregnancy is recognized

Interactions

  • Insulin or sulfonylureas: higher risk of low blood sugar
  • Oral medicines, especially narrow-margin ones such as warfarin: slowed stomach emptying may change absorption
  • Birth control pills: may be less effective; the label advises a non-oral or added barrier method around starting and dose increases

Serious risks

  • Severe stomach and bowel side effects
  • Kidney injury from dehydration
  • Gallbladder disease
  • Acute pancreatitis
  • Serious allergic reactions, including anaphylaxis and angioedema
  • Low blood sugar with insulin or sulfonylureas, and inhaling stomach contents during anesthesia

Common side effects

  • nausea
  • diarrhea
  • vomiting
  • constipation
  • abdominal pain
  • indigestion
  • injection-site reactions
  • hair loss

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Zepbound (tirzepatide) prescribing information ↗

Key precautions

Gastrointestinal reactions, dehydration, pancreatic and gallbladder concerns, and thyroid-tumor warnings matter. Pregnancy planning, oral contraception, and other diabetes medicines require specific clinical review.

Source: MedlinePlus: Tirzepatide injection ↗

Regulatory status

U.S. FDA approval
Approved
Mounjaro (NDA 215866, approved May 2022) for type 2 diabetes in adults, extended to children 10 and older in December 2025, and in August 2026 to lower the risk of heart attack, stroke and heart-related death in high-risk adults with type 2 diabetes; Zepbound (NDA 217806, approved November 2023) for chronic weight management and obstructive sleep apnea with obesity. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not prohibited. Tirzepatide markers are on WADA's 2026 Monitoring Program (tracked for misuse patterns, not banned). source

FDA actions

  • FDA proposed excluding tirzepatide (with semaglutide and liraglutide) from the 503B bulks list, finding no clinical need for outsourcing facilities to compound it from bulk. (2026-04-30) source
  • FDA statement announcing intent to restrict GLP-1 APIs used in mass-marketed non-approved compounded drugs and to act on misleading marketing. (2026-02-06) source
  • FDA page on risks of unapproved and compounded GLP-1 drugs, including fraudulent compounded tirzepatide and "research use only" sellers (updated October 1, 2026). (2026-10-01) source
  • FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Across 126 randomized trials (134,253 patients), NAION occurred 6.4 times per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or other diabetes drugs. FDA advises patients to contact a health care professional right away if they notice sudden vision loss in one eye, blind spots, color distortion or blurry spots, and says anyone who has had NAION should talk with their health care professional about whether to continue the medicine. (2026-11-09) source

Other notes

  • Tirzepatide is one of the GLP-1 active ingredients covered by FDA Import Alert 66-80 (detention without physical examination of GLP-1 bulk drug substances from non-green-listed makers; revised September 2026). source
  • WADA 2026 Monitoring Program includes markers of tirzepatide (in and out of competition). source
  • Canada, November 6, 2026: Health Canada warned consumers not to buy or inject unauthorized peptides sold online after lab tests of vials seized from a Chinese supplier found bacteria, including Acinetobacter seifertii, Acinetobacter nosocomialis and Cutibacterium acnes. It seized over 11,400 vials from the supplier and two Canadian online retailers, whose websites are no longer active. Unauthorized products sold as tirzepatide were among the example products listed. Authorized drugs for sale in Canada carry an 8-digit Drug Identification Number (DIN) on the label. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical uses & product context

The medication reference covers selected diabetes and weight-management populations and obstructive sleep apnea in adults with obesity. The exact product label defines eligibility and use.

Source: MedlinePlus: Tirzepatide injection ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. The approved medicine is available only with a prescription, through a pharmacy. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).

Mechanism & research rationale

It activates GIP and GLP-1 receptor pathways. Effects on glucose regulation, stomach emptying, and appetite are evaluated through indication-specific clinical trials.

Source: MedlinePlus: Tirzepatide injection ↗

Molecular structure

Tirzepatide: 2d molecular structure. The defined parent-peptide record CID 166567236 is shown; salt forms and other records can differ.⤢ Enlarge 2D
2D molecular structureThe defined parent-peptide record CID 166567236 is shown; salt forms and other records can differ.PubChem · CID 166567236 ↗

Questions worth asking

  • Which exact product is being discussed?
  • Is a podcast describing a study, an approved indication, or a personal experience?
  • Mounjaro, Zepbound, compounded preparations, and research products have distinct identities.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Are Mounjaro and Zepbound the same indication?

No. They contain the same molecule but have distinct product-label contexts.

Source: MedlinePlus: Tirzepatide injection ↗

Does SURMOUNT-1 validate every seller’s tirzepatide?

No. A study of a controlled pharmaceutical preparation cannot establish another product’s identity, potency, or clinical safety.

Source: Tirzepatide Once Weekly for the Treatment of Obesity. ↗

What does the SURPASS-2 direct comparison in type 2 diabetes study show, and what does it not?

This is a direct comparison, but only for its actual regimens, population, and outcomes. HbA1c percentage points and percentage weight change are different measures. Open-label design; the semaglutide comparator was its diabetes dose, not the higher weight-management dose. It is not a universal ranking across all products or doses. Funded by Eli Lilly.

Source: Frias et al. · NEJM · SURPASS-2 · 2021 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

PUT THE EVIDENCE IN CONTEXT

Research guides

RESEARCH FIELD GUIDE

GLP-1s and keto: a real-food playbook for losing fat, not muscle

A GLP-1 medicine turns down your appetite. What you eat with that smaller appetite decides how much of the weight you lose is fat and how much is muscle. Lived experience and the published research on cutting carbs, ketones, electrolytes, kidney stones, muscle, fasting, real food and sleep, including where the evidence is thin.

Read the guide →

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Tirzepatide

Download illustration ↓Source record ↗
Tirzepatide 2d molecular structure

The defined parent-peptide record CID 166567236 is shown; salt forms and other records can differ.